Company performance
Current Price
as of Jan 21, 2025$0.76
P/E Ratio
N/A
Market Cap
$13.89M
Loading...
Description
BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Gaithersburg, MD.
Metrics
Overview
- HQGaithersburg, MD
- SectorHealth Technology
- IndustryBiotechnology
- TickerPHGE
- Price$0.7644-0.36%
Trading Information
- Market cap$13.89M
- Float62.21%
- Average Daily Volume (1m)111,476
- Average Daily Volume (3m)114,403
- EPS-$3.53
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income$5.07M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$10.21M
- EV$20.43M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B0.72
Documents
SEC Filings
Factset Street Account